FY2025 Earnings Estimate for Omeros Issued By HC Wainwright

Key Points

• HC Wainwright raised its FY2025 earnings estimate for Omeros to ($2.15) per share, improving from a prior estimate of ($2.18), with a "Buy" rating and a target price of $20.00.
• Omeros reported ($0.53) earnings per share for the last quarter, exceeding expectations, while achieving a revenue of $28.60 million against an expectation of $0.31 million.
• The stock currently has an average rating of "Moderate Buy" with various ratings from analysts, including two "Strong Buy", three "Buy", two "Hold", and one "Sell".

Omeros Corporation (NASDAQ:OMER - Free Report) - Research analysts at HC Wainwright increased their FY2025 earnings per share estimates for Omeros in a research report issued on Wednesday, October 15th. HC Wainwright analyst B. Folkes now expects that the biopharmaceutical company will post earnings of ($2.15) per share for the year, up from their previous estimate of ($2.18). HC Wainwright currently has a "Buy" rating and a $20.00 target price on the stock. The consensus estimate for Omeros' current full-year earnings is ($3.09) per share. HC Wainwright also issued estimates for Omeros' Q4 2025 earnings at ($0.55) EPS, FY2026 earnings at ($1.84) EPS, FY2027 earnings at ($0.76) EPS, FY2028 earnings at $0.47 EPS and FY2029 earnings at $1.96 EPS.

Omeros (NASDAQ:OMER - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.02. The firm had revenue of $28.60 million for the quarter, compared to analysts' expectations of $0.31 million.

Other equities analysts have also issued research reports about the stock. WBB Securities reiterated a "strong-buy" rating and set a $45.00 price objective on shares of Omeros in a research report on Wednesday. D. Boral Capital restated a "buy" rating and set a $36.00 target price on shares of Omeros in a research report on Wednesday. Needham & Company LLC reiterated a "hold" rating on shares of Omeros in a research report on Wednesday. Wall Street Zen upgraded Omeros from a "sell" rating to a "hold" rating in a research report on Saturday, September 20th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Omeros in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $27.50.

Omeros Stock Performance

OMER stock opened at $9.83 on Friday. The firm has a fifty day moving average price of $4.49 and a 200 day moving average price of $4.55. Omeros has a fifty-two week low of $2.95 and a fifty-two week high of $13.60. The firm has a market cap of $669.03 million, a PE ratio of -4.66 and a beta of 2.32.

Hedge Funds Weigh In On Omeros

A number of large investors have recently bought and sold shares of OMER. Wellington Management Group LLP purchased a new stake in Omeros in the 1st quarter valued at about $1,118,000. Nuveen LLC bought a new stake in shares of Omeros during the first quarter valued at approximately $938,000. Brevan Howard Capital Management LP purchased a new stake in shares of Omeros in the second quarter valued at approximately $316,000. Marshall Wace LLP boosted its holdings in shares of Omeros by 15.1% in the second quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company's stock valued at $2,224,000 after purchasing an additional 97,224 shares during the period. Finally, Vanguard Group Inc. grew its stake in Omeros by 3.0% in the first quarter. Vanguard Group Inc. now owns 3,237,256 shares of the biopharmaceutical company's stock worth $26,610,000 after purchasing an additional 95,599 shares in the last quarter. Hedge funds and other institutional investors own 48.79% of the company's stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.